ANIK Stock Overview
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 3/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for ANIK from our risk checks.
Anika Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$25.54 |
52 Week High | US$29.26 |
52 Week Low | US$16.54 |
Beta | 0.75 |
1 Month Change | 0.55% |
3 Month Change | 12.81% |
1 Year Change | -10.51% |
3 Year Change | -37.39% |
5 Year Change | -15.71% |
Change since IPO | 629.71% |
Recent News & Updates
Recent updates
Is There An Opportunity With Anika Therapeutics, Inc.'s (NASDAQ:ANIK) 44% Undervaluation?
Jan 30Companies Like Anika Therapeutics (NASDAQ:ANIK) Can Afford To Invest In Growth
Aug 03Anika Therapeutics: New Share Price Low May Imply New Upside Opportunity
Mar 11Are Investors Undervaluing Anika Therapeutics, Inc. (NASDAQ:ANIK) By 48%?
Jun 25Anika Therapeutics (ANIK) Presents At UBS Global Healthcare Virtual Conference - Slideshow
May 28Anika Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation
May 07How Much Are Anika Therapeutics, Inc. (NASDAQ:ANIK) Insiders Taking Off The Table?
Mar 16Anika Therapeutics (NASDAQ:ANIK) Seems To Use Debt Quite Sensibly
Feb 09An Intrinsic Calculation For Anika Therapeutics, Inc. (NASDAQ:ANIK) Suggests It's 32% Undervalued
Jan 13If You Had Bought Anika Therapeutics' (NASDAQ:ANIK) Shares A Year Ago You Would Be Down 21%
Dec 18Anika Therapeutics, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 06Shareholder Returns
ANIK | US Biotechs | US Market | |
---|---|---|---|
7D | -0.2% | 0.9% | 0.4% |
1Y | -10.5% | 10.3% | 28.8% |
Return vs Industry: ANIK underperformed the US Biotechs industry which returned 9.6% over the past year.
Return vs Market: ANIK underperformed the US Market which returned 29.5% over the past year.
Price Volatility
ANIK volatility | |
---|---|
ANIK Average Weekly Movement | 4.4% |
Biotechs Industry Average Movement | 11.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ANIK has not had significant price volatility in the past 3 months.
Volatility Over Time: ANIK's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1983 | 357 | Cheryl Blanchard | https://www.anika.com |
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief.
Anika Therapeutics, Inc. Fundamentals Summary
ANIK fundamental statistics | |
---|---|
Market cap | US$374.47m |
Earnings (TTM) | -US$82.67m |
Revenue (TTM) | US$166.66m |
2.2x
P/S Ratio-4.5x
P/E RatioIs ANIK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ANIK income statement (TTM) | |
---|---|
Revenue | US$166.66m |
Cost of Revenue | US$62.83m |
Gross Profit | US$103.84m |
Other Expenses | US$186.50m |
Earnings | -US$82.67m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -5.64 |
Gross Margin | 62.30% |
Net Profit Margin | -49.60% |
Debt/Equity Ratio | 0% |
How did ANIK perform over the long term?
See historical performance and comparison